Understand the source comparison
ARA-290 for Inflammation: Type Comparison
Small fiber neuropathy (autoimmune) Direct nerve repair + endothelial protection Phase 2 RCT (positive) 4 mg SC 3×/week × 4 weeks Strongest published evidence. Nerve fiber improvement confirmed by imaging Diabetic peripheral neuropathy Mitochondrial protection
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Small fiber neuropathy (autoimmune)
- Direct nerve repair + endothelial protection
- Phase 2 RCT (positive)
- 4 mg SC 3×/week × 4 weeks
- Strongest published evidence. Nerve fiber improvement confirmed by imaging
- Diabetic peripheral neuropathy
- Mitochondrial protection + cytokine modulation
- Phase 2 RCT (trend positive)
- 4–8 mg SC 3×/week × 4 weeks
- Dose-dependent trend; did not meet primary endpoint but showed secondary pain measure improvement
- Sarcoidosis-related inflammation
- Innate repair receptor activation + reduced TNF-alpha
- Pain reduction + objective nerve fiber density increase
- Ischemic injury (cardiac, renal)
- Reduced apoptosis + endothelial stabilization
- Preclinical (animal models)
- Variable: 100–300 mcg/kg in rodents
- Promising preclinical signal; no human trials yet
- Rheumatoid arthritis
- Cytokine modulation (IL-6, TNF-alpha)
- Preclinical only
- Not established in human RA studies
- Mechanism suggests potential but no clinical data
- Metabolic syndrome inflammation
- Reduces oxidative stress + improves insulin signaling
- Preclinical (rodent models)
- Not yet tested in human metabolic syndrome
- Indirect benefit via improved endothelial function